Praxis Precision Medicines to Participate in Upcoming Fireside Chat
BOSTON, Aug. 29, 2025 (GLOBE NEWSWIRE) -- , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that CEO Marcio Souza will be participating a virtual fireside chat hosted by Ritu Baral, Biotechnology Analyst, TD Cowen on September 2, 2025 at 10:00amEST to discuss content shared by Praxis at the 36th International Epilepsy Consortium (IEC).
The registration link for the fireside chat can be found .
The overview of Praxis’ posters and presentation at the IEC event can be found .
About Praxis
Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating insights from genetic epilepsies into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. Praxis is applying genetic insights to the discovery and development of therapies for rare and more prevalent neurological disorders through our proprietary small molecule platform, Cerebrum™, and antisense oligonucleotide (ASO) platform, Solidus™, using our understanding of shared biological targets and circuits in the brain. Praxis has established a diversified, multimodal CNS portfolio including multiple programs across epilepsy and movement disorders, with four clinical-stage product candidates. For more information, please visit and follow us on , , and .
Investor Contact: Praxis Precision Medicines 857-702-9452 Media Contact: Dan Ferry Life Science Advisors 617-430-7576
